IP Library Patent Application 13246287
Patent Application
App. No. 13/246,287

COMPOSITIONS FOR BOWEL PREPARATION AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/246,287
Abstract

The present invention relates to formulations and kits for gastrointestinal cleansing and to therapeutic methods thereof.

Claims (23)

1 . A method of cleansing the GI tract of a subject, comprising:

administering about 48 mg of sodium phosphate with about 2 L of aqueous solution to a subject who has not recently had a kidney biopsy indicating kidney damage due to excess phosphate.

2 . A method of cleansing the GI tract of a subject, comprising:

determining weather a subject is a candidate for a sodium phosphate GI cleanser;

providing about 48 mg of sodium phosphate to a subject; and

instructing the subject to ingest the sodium phosphate with 2 L of aqueous solution.

3 . The method of claim 2 , wherein determining comprises a biopsy of the kidney, wherein if the biopsy shows damage to the kidney due to too much phosphate, the subject is not a candidate for a sodium phosphate GI cleanser.

4 . A method of determining if a subject is a candidate for cleansing the GI tract with sodium phosphate comprising:

determining the phosphate levels in a kidney of the subject;

wherein normal levels of phosphate in the kidney indicates that the subject is a candidate for cleansing of the GI tract with sodium phosphate.

5 . The method of claim 4 , wherein a biopsy is performed to obtain a sample of the kidney from the subject.

6 . The method of claim 4 , further comprising administering to a subject determined to be a candidate about 48 mg of sodium phosphate with about 2 L of aqueous solution.

7 . A method of determining if a subject is a candidate for cleansing the GI tract with sodium phosphate comprising:

determining if the subject has normal renal function;

wherein normal renal function indicates that the subject is a candidate for cleansing of the GI tract with sodium phosphate.

8 . The method of claim 7 , wherein normal renal function is characterized by creatinine clearance of greater than or equal to 30 mL/minute.

9 . The method of claim 8 , wherein further comprising administering to a subject determined to be a candidate about 48 mg of sodium phosphate with about 2 L of aqueous solution.

10 . A method of determining if a subject is a candidate for cleansing the GI tract with sodium phosphate comprising:

determining if the subject is a candidate for sodium phosphate purgative cleansing by one or more of: determining age, determining renal function, or determining phosphate level of the kidney; and

administering to a subject determined to be a candidate about 48 mg of sodium phosphate with about 2 L of aqueous solution.

11 . The method of claim 10 , wherein if a subject is determined to be of increased age, they are not a candidate.

12 . The method of claim 10 , wherein determined to have abnormal levels of phosphate in the kidney they are not a candidate.

13 . The method of claim 10 , if a subject has renal function characterized by creatinine clearance of greater than or equal to 30 mL/minute they are a candidate.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT Recorded Apr 2, 2015
From: GLYCYX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 035364/0396 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2015
From: JEFFERIES FINANCE LLC
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 035353/0661 →
SECURITY AGREEMENT Recorded Jan 2, 2014
From: SALIX PHARMACEUTICALS, LTD.
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 031896/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2011
From: PATTON, STEPHANA
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 027163/0393 →